Nov 30,2022

PreciseDx announces new collaboration with Laboratory of Pathology at Albert Schweitzer Hospital Dordrecht

PreciseDx, a leading AI company that uses the analysis of morphological features of histology slides to provide more precise patient-specific risk information, today announced a partnership with the Laboratory of Pathology in Dordrecht, the Netherlands. The laboratory is responsible for the pathology of both the Albert Schweitzer Hospital in Dordrecht and the Beatrix Hospital in Gorinchem, both in the Netherlands. Through this agreement, the Laboratory of Pathology will study the performance of PreciseDx's AI-driven Cancer Risk Stratification platform and confirm the accuracy of the stage and its role in the decision-making process.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Nov 30,2022

Selin Kurnaz, Massive Bio CEO Delivered a Keynote Speech at the 8th Annual CMPRR Summit

Massive Bio CEO and Co-Founder Selin Kurnaz, PhD, delivered a keynote speech at the 8th Annual Clinical Monitoring and Patient Recruitment Retention (CMPRR) Summit, which was held in Barcelona, Spain, on November 22-23, 2022. Sessions presented during the two-day event examined the role of technologies such as the Internet of Things and artificial intelligence (AI), quality standards, compliance oversight, risk-based and centralized monitoring, clinical monitoring, and new approaches to patient engagement, among other critical topics.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 30,2022

AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022

AstraZeneca will present 47 abstracts showcasing new data from across its haematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, 10 to 13 December 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting

COTA is honored to announce that our team has directly contributed to three abstracts accepted for poster presentation at the December conference. Two of these studies were conducted in close partnership with researchers from the FDA. Four other accepted abstracts leverage COTA’s real-world data (RWD) to support their crucial work around hematologic cancer.

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference

BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 02,2022

November 2022 Precision Prevention News: Six to Skim

The latest in precision prevention news, curated for CancerIQ's community of oncologists, genetic counselors, breast centers, primary care providers, and anyone interested in staying ahead of cancer.

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 02,2022

Contributed: The future of digital cancer care

Flare Capital Partners' Ian Chiang and Jonathon George discuss emerging trends in digital health-enabled cancer care. In part one of this article, the contributers highlighted the various components of end-to-end cancer care delivery and management and how innovators have emerged to address today’s unmet needs.

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

West Midlands to digitally transform cancer diagnosis across 17 trusts following digital pathology go-live with Sectra

NHS patients throughout the West Midlands are to benefit from a digital pathology programme, designed to help reduce cancer backlogs, transform services, and improve the speed and accuracy of cancer diagnosis. Delivered in partnership with medical imaging technology provider Sectra, the programme will help to tackle cancer backlogs by providing pathologists with the digital tools needed to better collaborate, share expertise and capacity, prioritise urgent cases and manage growing demand across the entire region

COLLABORATION PARTNERSHIP

#institution

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

The Digital Future Of Pathology

Pathology is the motor that drives healthcare to understand diseases. Digital technologies could push the field into becoming more efficient and more scalable. These past few years have brought some grand breakthroughs, which are discussed in detail in this article. The first major milestone was September 2021 – the date when the first AI-based pathology product – Paige Prostate, a clinical-grade AI solution for prostate cancer detection – received FDA clearance for clinical use. It was followed by a CE mark for the Paige Breast Lymph Node Detection within a year.

PRODUCT

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Dec 06,2022

Tempus Announces Six Abstracts Accepted for Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the 2022 San Antonio Breast Cancer Symposium, which convenes from December 6-10, in San Antonio, Texas. Tempus continues to be a leader in advancing breast cancer research, demonstrated in the six abstracts being presented this year.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY